Study Assesses Sublingual Fentanyl Vs Morphine for CA Pain

Share this content:
Study Assesses Sublingual Fentanyl Vs Morphine for CA Pain
Study Assesses Sublingual Fentanyl Vs Morphine for CA Pain

THURSDAY, Jan. 26, 2017 (HealthDay News) -- For patients with severe cancer pain episodes, fentanyl sublingual tablets (FST) offer analgesia with modest to moderate increased risk of lower efficacy compared with subcutaneous morphine (SCM), according to a study published online Jan. 23 in the Journal of Clinical Oncology.

Ernesto Zecca, from the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, and colleagues tested the non-inferiority of FST versus SCM during the first 30 minutes after administration. Patients receiving stable opioid therapy and experiencing severe pain were randomized to receive 100 µg FST (57 patients) or 5 mg SCM (56 patients). The authors assessed average pain intensity (PI) at 10, 20, and 30 minutes after administration on a 0 to 10 numerical rating scale.

The researchers found that in both groups the baseline mean PI was 7.5. At 10, 20 and 30 minutes after administration, the mean average PIs were 5.0 and 4.5 for FST and SCM, respectively; the 95 percent confidence interval of the between-group difference included the non-inferiority margin of −0.6 (−0.49; 95 percent confidence interval, −1.10 to 0.09). Receipt of a second drug dose after 30 minutes occurred more frequently in patients taking FST versus SCM (51 versus 37 percent). Both treatments were well tolerated. Most patients (93 percent) preferred the sublingual administration.

"This trial did not show non-inferiority of FST versus SCM within the chosen non-inferiority margin," the authors write. "FST provides analgesia with modest to moderate increased risk of lower efficacy compared with SCM."

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Parkinson's Add-On Drug Xadago

FDA Approves New Parkinson's Add-On Drug Xadago

To help prevent 'off' episodes among users of levodopa/carbidopa

Infant Mortality Down in United States From 2005 to 2014

Infant Mortality Down in United States From 2005 ...

Largest decreases seen for infants of Asian or Pacific Islander and non-Hispanic black women

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive alveolar recruitment strategy linked to less severe pulmonary complications after cardiac sx

is free, fast, and customized just for you!

Already a member?

Sign In Now »